Literature DB >> 20876372

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Adam Belley1, Geoffrey A McKay, Francis F Arhin, Ingrid Sarmiento, Sylvain Beaulieu, Ibthihal Fadhil, Thomas R Parr, Gregory Moeck.   

Abstract

Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. In this study, we demonstrate that oritavancin causes bacterial membrane depolarization and permeabilization leading to cell death of Gram-positive pathogens and that these effects are attributable to the 4'-chlorobiphenylmethyl group of the molecule.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20876372      PMCID： PMC2981232          DOI： 10.1128/AAC.00760-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Authors:  Francis F Arhin; Ingrid Sarmiento; Thomas R Parr; Gregory Moeck
Journal:  J Antimicrob Chemother       Date:  2009-08-04       Impact factor: 5.790

3.  Vancomycin and oritavancin have different modes of action in Enterococcus faecium.

Authors:  Gary J Patti; Sung Joon Kim; Tsyr-Yan Yu; Evelyne Dietrich; Kelly S E Tanaka; Thomas R Parr; Adel Rafai Far; Jacob Schaefer
Journal:  J Mol Biol       Date:  2009-07-01       Impact factor: 5.469

4.  Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus.

Authors:  Sung Joon Kim; Manmilan Singh; Jacob Schaefer
Journal:  J Mol Biol       Date:  2009-06-16       Impact factor: 5.469

5.  Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.

Authors:  Carmela T M Mascio; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

6.  Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization.

Authors:  Oscar Domenech; Grégory Francius; Paul M Tulkens; Françoise Van Bambeke; Yves Dufrêne; Marie-Paule Mingeot-Leclercq
Journal:  Biochim Biophys Acta       Date:  2009-05-18

7.  Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors:  Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

8.  Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

Authors:  Christopher S Lunde; Stephanie R Hartouni; James W Janc; Mathai Mammen; Patrick P Humphrey; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

9.  Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

Authors:  Geoffrey A McKay; Sylvain Beaulieu; Francis F Arhin; Adam Belley; Ingrid Sarmiento; Thomas Parr; Gregory Moeck
Journal:  J Antimicrob Chemother       Date:  2009-04-15       Impact factor: 5.790

10.  Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.

Authors:  Sung Joon Kim; Lynette Cegelski; Dirk Stueber; Manmilan Singh; Evelyne Dietrich; Kelly S E Tanaka; Thomas R Parr; Adel Rafai Far; Jacob Schaefer
Journal:  J Mol Biol       Date:  2008-01-17       Impact factor: 5.469
View more
  31 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function.

Authors:  Zsolt Szűcs; Magdolna Csávás; Erzsébet Rőth; Anikó Borbás; Gyula Batta; Florent Perret; Eszter Ostorházi; Réka Szatmári; Evelien Vanderlinden; Lieve Naesens; Pál Herczegh
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  N-Terminus Alkylation of Vancomycin: Ligand Binding Affinity, Antimicrobial Activity, and Site-Specific Nature of Quaternary Trimethylammonium Salt Modification.

Authors:  Zhi-Chen Wu; Nicholas A Isley; Dale L Boger
Journal:  ACS Infect Dis       Date:  2018-08-08       Impact factor: 5.084

4.  Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.

Authors:  Cesar A Arias; Rodrigo E Mendes; Matthew G Stilwell; Ronald N Jones; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

5.  Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.

Authors:  Beverlie Baquir; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Lin Lin; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2012-04       Impact factor: 9.079

Review 6.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

7.  Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.

Authors:  Daniela Münch; Ina Engels; Anna Müller; Katrin Reder-Christ; Hildegard Falkenstein-Paul; Gabriele Bierbaum; Fabian Grein; Gerd Bendas; Hans-Georg Sahl; Tanja Schneider
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

8.  Oritavancin (Orbactiv): A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections.

Authors:  Samantha Rosenthal; Arnold G Decano; Aiman Bandali; Denise Lai; Gregory E Malat; Tiffany E Bias
Journal:  P T       Date:  2018-03

9.  Trichlorination of a Teicoplanin-Type Glycopeptide Antibiotic by the Halogenase StaI Evades Resistance.

Authors:  Grace Yim; Wenliang Wang; Andrew C Pawlowski; Gerard D Wright
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

10.  Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Authors:  Adam Belley; David Lalonde Seguin; Francis Arhin; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.